Cargando…

FGFR3 signaling and function in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) accounts for 16% of breast cancers and represents an aggressive subtype that lacks targeted therapeutic options. In this study, mass spectrometry (MS)-based tyrosine phosphorylation profiling identified aberrant FGFR3 activation in a subset of TNBC ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chew, Nicole J., Nguyen, Elizabeth V., Su, Shih-Ping, Novy, Karel, Chan, Howard C., Nguyen, Lan K., Luu, Jennii, Simpson, Kaylene J., Lee, Rachel S., Daly, Roger J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986078/ https://www.ncbi.nlm.nih.gov/pubmed/31987043 http://dx.doi.org/10.1186/s12964-019-0486-4

Ejemplares similares

The pseudokinase NRBP1 activates Rac1/Cdc42 via P-Rex1 to drive oncogenic signalling in triple-negative breast cancer
por: Yang, Xue, et al.
Publicado: (2023)

Using a Quantitative High-Throughput Screening Platform to Identify Molecular Targets and Compounds as Repurposing Candidates for Endometriosis
por: Churchill, Molly L., et al.
Publicado: (2023)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
por: Sung, Vanessa Y. C., et al.
Publicado: (2021)

Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models
por: Chew, Nicole J., et al.
Publicado: (2021)

Methodology for the identification of small molecule inhibitors of the Fanconi Anaemia ubiquitin E3 ligase complex
por: Sharp, Michael F., et al.
Publicado: (2020)

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
por: Lei, Josh Haipeng, et al.
Publicado: (2021)

Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer
por: Nedeljković, Milica, et al.
Publicado: (2019)

FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts
por: Wu, Yushen, et al.
Publicado: (2022)

Characterization of the Src-regulated kinome identifies SGK1 as a key mediator of Src-induced transformation
por: Ma, Xiuquan, et al.
Publicado: (2019)

Differential responses to kinase inhibition in FGFR2-addicted triple negative breast cancer cells: a quantitative phosphoproteomics study
por: Cunningham, Debbie L., et al.
Publicado: (2020)

Brassinin Promotes the Degradation of Tie2 and FGFR1 in Endothelial Cells and Inhibits Triple-Negative Breast Cancer Angiogenesis
por: Gu, Yuan, et al.
Publicado: (2022)

Radiation therapy attenuates lymphatic vessel repair by reducing VEGFR-3 signalling
por: Pillay, Vinochani, et al.
Publicado: (2023)

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021)

Signalome-wide assessment of host cell response to hepatitis C virus
por: Haqshenas, Gholamreza, et al.
Publicado: (2017)

Metabolic profiling and in vitro assessment of anthelmintic fractions of Picria fel-terrae Lour.
por: Kumarasingha, Rasika, et al.
Publicado: (2016)

High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids
por: Choo, Nicholas, et al.
Publicado: (2021)

The Relationship Between Fibroblastic Growth Factor Receptor-1 (FGFR1) Gene Amplification in Triple Negative Breast Carcinomas and Clinicopathological Prognostic Factors
por: Jafarian, Amir Hossein, et al.
Publicado: (2019)

Phenotypic Consequences of SLC25A40-ABCB1 Fusions beyond Drug Resistance in High-Grade Serous Ovarian Cancer
por: Pishas, Kathleen I., et al.
Publicado: (2021)

Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling
por: Szybowska, Patrycja, et al.
Publicado: (2021)

Immunotherapy Treatment for Triple Negative Breast Cancer
por: Berger, Elizabeth R., et al.
Publicado: (2021)

Rad51 supports triple negative breast cancer metastasis
por: Wiegmans, Adrian P, et al.
Publicado: (2014)

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022)

S100A4 Is Involved in Stimulatory Effects Elicited by the FGF2/FGFR1 Signaling Pathway in Triple-Negative Breast Cancer (TNBC) Cells
por: Santolla, Maria Francesca, et al.
Publicado: (2021)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

The Receptor Tyrosine Kinase FGFR4 Negatively Regulates NF-kappaB Signaling
por: Drafahl, Kristine A., et al.
Publicado: (2010)

FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
por: Quintanal-Villalonga, Álvaro, et al.
Publicado: (2020)

Role of Postnatal Expression of Fgfr1 and Fgfr2 in Testicular Germ Cells on Spermatogenesis and Fertility in Mice
por: Li, Shengqiang, et al.
Publicado: (2014)

FGFR1 and WT1 are markers of human prostate cancer progression
por: Devilard, Elizabeth, et al.
Publicado: (2006)

Detection of G338R FGFR2 mutation in a Vietnamese patient with Crouzon syndrome
por: Luong, Anh Lan Thi, et al.
Publicado: (2019)

Clinical trials of immunotherapy in triple-negative breast cancer
por: Howard, Frederick M., et al.
Publicado: (2022)

Immunotherapy for Triple-Negative Breast Cancer
por: Cao, Yifeng, et al.
Publicado: (2021)

Intestinal Microbiota Influence Doxorubicin Responsiveness in Triple-Negative Breast Cancer
por: Bawaneh, Alaa, et al.
Publicado: (2022)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

Knocking down the obstacles to functional genomics data sharing
por: Simpson, Kaylene J., et al.
Publicado: (2017)

Development and characterization of two human triple‐negative breast cancer cell lines with highly tumorigenic and metastatic capabilities
por: Su, Yanrong, et al.
Publicado: (2016)

Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas
por: Granberg, Kirsi J, et al.
Publicado: (2017)

The Inhibition of the FGFR/PI3K/Akt Axis by AZD4547 Disrupts the Proangiogenic Microenvironment and Vasculogenic Mimicry Arising from the Interplay between Endothelial and Triple-Negative Breast Cancer Cells
por: Morales-Guadarrama, Gabriela, et al.
Publicado: (2023)

Triple Negative Breast Cancer – An Overview
por: Aysola, Kartik, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_vm9vt5pacs3q09e0uvm6u7e9p6